World’s First Approved Biosimilar toActemra ® Guangzhou, China--(BUSINESSWIRE)-- Bio-Thera Solutions, Ltd. (SH: 688177), a commercial-stagebiopharmaceutical company, announced thattheChina National Medical Products Administration(NMPA) hasapproved BAT1806, a biosimilar of Actemra ® (tocilizumab)...
DetailsJuly 25, 2018-- Bio-Thera Solutions, a clinical-stage pharmaceutical company, today announced that dosing has begun ina Phase I clinical study to compare the pharmacokinetics and safety of BAT1806, a proposed biosimilar of Actemra ® (tocilizumab), to US-sourced Actemra ® and EU-sourced RoActemra ®...
In March 2018, BAT4306F, the recombinant glycosylation-modified anti-human-CD20 monoclonal antibody solution for injection, approved for phase I clinical trials in China. BAT4306Fis a next generation anti-CD20 monoclonal antibody. The CD20 receptor is a validated drug target with monoclonal antibodi...
GUANGZHOU, CHINA, March 29, 2018 – Bio-Thera Solutions, a clinical-stage biopharmaceutical company developing a pipeline of innovative therapies and a pipeline of biosimilars, today announced the company will present two posters at the 2018 American Association for Cancer Research ("AACR") Annual ...
